Aurora Cannabis Provides Business Update; Accretive Acquisition of Safari Flower Company and Leading European Performance Expected to Fuel International Growth in the Fiscal Second Quarter 2027 and Beyond

Aurora Cannabis reaffirmed FY2027 Q2 guidance for sequential quarterly net-revenue and adjusted-EBITDA growth, supported by international medical-cannabis expansion. The Safari Flower acquisition, following EU-GMP certification in July, is expected to add revenue and EBITDA, while Germany and Poland continue to drive profitable growth and Aurora holds the top revenue market share in Poland. The company is also expanding in the UK through the acquisitions of Internode Pharma and HAP Pharma, backed by $149 million of cash and no debt as of June 30, 2026.

Analysis

ACB’s near-term setup is constructive only if international growth converts into gross-margin expansion rather than being absorbed by distribution, integration and compliance costs. The strategic value of added EU-GMP supply is less incremental cultivation capacity than reduced stock-out risk in tightly regulated channels; reliable availability can win prescribing and pharmacy relationships that are sticky once established. That creates a plausible 6-18 month share-gain flywheel versus Canadian peers with weaker European infrastructure, notably TLRY and OGI, but it does not by itself establish pricing power.

The key issue for the next 1-3 months is quality of the reiterated outlook. “Sequential” growth is a low bar, while adjusted EBITDA can improve through mix, timing and acquisition accounting without equivalent operating cash-flow improvement. Cash plus no debt reduces acute solvency risk, but ongoing international investment and an available ATM create an asymmetric dilution overhang if working capital or acquisition integration consumes more cash than expected; equity-funded growth can cap multiple expansion even on a headline beat.

Consensus may overvalue EU regulatory optionality and underestimate market fragmentation: national reimbursement, physician adoption, import rules and local pharmacy economics can delay volume conversion despite formal market access. Conversely, a clean Q2 showing that international revenue outgrows operating expense, with stable realized pricing and no material cash burn, would force a rerating from a Canadian cannabis proxy toward a differentiated medical-export operator. This remains an earnings-validation trade, not a press-release trade.

Key Decisions for Investors

• Do not chase ACB on the reaffirmation. Establish a starter long only after Q2 confirms sequential revenue and adjusted EBITDA growth alongside stable or improving operating cash flow; add if international revenue growth exceeds consolidated growth and management quantifies acquisition contribution.
• For a 1-3 month event position, use a defined-risk ACB call spread expiring after Q2 results rather than common equity; size modestly because the likely upside is a multiple rerating while downside includes dilution and a credibility reset. Avoid the trade if implied volatility already prices a materially larger move than ACB’s prior earnings reactions.
• Pair expression for 6-12 months: long ACB / short TLRY in equal volatility-adjusted dollars, contingent on evidence that ACB’s European medical mix is producing superior EBITDA conversion. Falsify if ACB’s SG&A rises faster than revenue for two quarters, or if TLRY demonstrates equivalent EU profitability without incremental dilution.
• Monitor cash, restricted cash and short-term investments versus quarterly operating and investing outflows. A meaningful decline without corresponding revenue acceleration, an ATM issuance, or guidance that omits cash-flow progress should trigger exit from longs; these are more informative than adjusted EBITDA alone.